Amgen website. Amgen, Cytokinetics and Servier announce topline results from GALACTIC-HF, a phase 3 trial of omecamtiv mecarbil in patients with heart failure. Accessed October 15, 2020. http://investors.amgen.com/news-releases/news-release-details/amgen-cytokinetics-and-servier-announce-topline-results-galactic
Teerlink JR. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: the global approach to lowering adverse cardiac outcomes through improving contractility in heart failure (GALACTIC-HF) trial. Accessed October 15, 2020. https://www.abstractsonline.com/pp8/?&_ga=2.205885075.1446428122.1602780183-845841488.1602780183#!/9144/session/828
Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904-910.
Crespo-Leiro MG, Anker SD, Maggioni AP, et al; Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-625.
Delicce AV, Makaryus AN. Physiology, Frank Starling Law. 2020 Apr 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. PMID: 29262149.
Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365-2383.
Kaplinsky E, Mallarkey G. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs Context. 2018;7:212518.
Komajda M, Anker SD, Cowie MR, et al; QUALIFY Investigators. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514-522.
Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
Teerlink JR. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: the global approach to lowering adverse cardiac outcomes through improving contractility in heart failure (GALACTIC-HF) trial. Accessed October 15, 2020. https://www.abstractsonline.com/pp8/?&_ga=2.205885075.1446428122.1602780183-845841488.1602780183#!/9144/session/828
Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8:329-340.
Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC-HF: baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020 Sep 27 [Epub ahead of print]. doi: 10.1002/ejhf.2015.
Teerlink JR, Felker GM, McMurray JJ, et al; COSMIC-HF Investigators. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388:2895-2903.
Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121-128.
van der Wal HH, van Deursen VM, van der Meer P, Voors AA. Comorbidities in heart failure. Handb Exp Pharmacol. 2017;243:35-66.
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368-378.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Larry A. Allen, MD, MHS

Professor of Medicine, Kenneth Poirier Chair
Associate Head for Clinical Affairs, Cardiology
Medical Director, Advanced Heart Failure
University of Colorado School of Medicine
Aurora, Colorado, United States

Disclosures

Disclosure: Larry A. Allen, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; ACI Clinical; Amgen; Boston Scientific; Cytokinetics; Novartis

Piotr Ponikowski, MD, PhD, FESC

Professor
Head of Department of Heart Diseases
Medical University Wroclaw
Director, Centre for Heart Diseases
University Hospital
Wroclaw, Poland

Disclosures

Disclosure: Piotr Ponikowski, MD, PhD, FESC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Vascular; Amgen; AstraZeneca; Bayer; Berlin Chemie; Boehringer Ingelheim; Cibiem; Coridea; Impulse Dynamics; Novartis; Pfizer; Renal Guard Solutions; Servier; Vifor Pharma
Served as a speaker or a member of a speakers bureau for: Abbott Vascular; Amgen; AstraZeneca; Bayer; Berlin Chemie; Boehringer Ingelheim; Cibiem; Impulse Dynamics; Novartis; Pfizer; Renal Guard Solutions; Servier; Vifor Pharma
Received grants for clinical research from: Vifor Pharma

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Abbott labs

CPD

Emerging HFrEF Therapies: Sequencing Complexities in the Treatment Landscape

Authors: Larry A. Allen, MD, MHS; Piotr Ponikowski, MD, PhD, FESC
CPD Released: 2/24/2021
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 2/24/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and nephrologists.

The goal of this activity is to review limitations in the pharmacologic treatment of patients with heart failure with reduced ejection fraction (HFrEF) and new agents in clinical development that may have a future role in HFrEF treatment.

Upon completion of this activity, participants will:

Have increased knowledge regarding
- Barriers to optimal use of current therapies for the treatment of patients with HFrEF
- The role of new and emerging drug therapies for HFrEF treatment, including appropriate patient selection

Disclosures

Faculty

Larry A. Allen, MD, MHS

Professor of Medicine, Kenneth Poirier Chair
Associate Head for Clinical Affairs, Cardiology
Medical Director, Advanced Heart Failure
University of Colorado School of Medicine
Aurora, Colorado, United States

Disclosures

Disclosure: Larry A. Allen, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; ACI Clinical; Amgen; Boston Scientific; Cytokinetics; Novartis

Piotr Ponikowski, MD, PhD, FESC

Professor
Head of Department of Heart Diseases
Medical University Wroclaw
Director, Centre for Heart Diseases
University Hospital
Wroclaw, Poland

Disclosures

Disclosure: Piotr Ponikowski, MD, PhD, FESC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Vascular; Amgen; AstraZeneca; Bayer; Berlin Chemie; Boehringer Ingelheim; Cibiem; Coridea; Impulse Dynamics; Novartis; Pfizer; Renal Guard Solutions; Servier; Vifor Pharma
Served as a speaker or a member of a speakers bureau for: Abbott Vascular; Amgen; AstraZeneca; Bayer; Berlin Chemie; Boehringer Ingelheim; Cibiem; Impulse Dynamics; Novartis; Pfizer; Renal Guard Solutions; Servier; Vifor Pharma
Received grants for clinical research from: Vifor Pharma

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Abbott labs

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

Emerging Treatment Pathways For Chronic Heart Failure

From Medscape Education

CPD

Emerging HFrEF Therapies: Sequencing Complexities in the Treatment Landscape

Authors: Larry A. Allen, MD, MHS; Piotr Ponikowski, MD, PhD, FESCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 2/24/2021

Valid for credit through: 2/24/2022

processing....

Deutsche Untertitel

« Return to: Emerging HFrEF Therapies: Sequencing Complexities in the Treatment Landscape

Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Larry A. Allen, MD, MHS

Piotr Ponikowski, MD, PhD, FESC

Editor

Anne M. Sendaydiego, PharmD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

Emerging HFrEF Therapies: Sequencing Complexities in the Treatment Landscape

Target Audience and Goal Statement

Disclosures

Faculty

Larry A. Allen, MD, MHS

Piotr Ponikowski, MD, PhD, FESC

Editor

Anne M. Sendaydiego, PharmD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Emerging HFrEF Therapies: Sequencing Complexities in the Treatment Landscape

Deutsche Untertitel